New products 11Filtration+Separation November 2005

Millipore adds new PES Filtersto rangeMillipore has introduced itsMillipore Express SHR(Sterile High-Retention)filters, which the companysays provide sterilising-gradeperformance andmycoplasma removal acrossa range of applicationsincluding cell culture mediaand media additives; processintermediates; and otherbiological fluids.

“The filters can delivervalidated sterilising-gradefiltration and reliablemycoplasma removal forenhanced sterility assurance, highflow rates for improved processefficiency, togethether with anon-board PES membrane prefilterfor extended filter capacity andlower filtration costs,” thecompany claims.

The sterilising-grade MilliporeExpress SHR 0.1-µm rated filtersare available in a range of formats

including; membrane disks (25mm, 47 mm, 90 mm and 142mm); cartridge filters ranging insize from 5- to 30-inches;OptiScale disposable scalingdevices; and Opticap XL and XLTautoclavable or gamma-compatible capsules.

www.millipore.com

Millipore’s new Express SHR (Sterile High-Retention) range of filters

Pall platelet product gets USFDA clearance Pall Corp has obtained FDAclearance to market its newAcrodose PL system.

The company reports that this isthe first whole-blood-derived-platelet system – for pre-storagepooling and testing ofleukoreduced whole-blood-derived platelets – resulting in atransfusion-ready product for thehospital. “This unique productincreases the availability oflifesaving platelets, enhancespatient safety and is more cost-effective for the hospital,” asource explained.

Platelets are derived from donorsin either a one-to-two hourprocedure called apheresis, orfrom standard whole bloodcollections. Apheresed plateletsare limited by donor availability,and are also time-consuming andcapital intensive to obtain.

The new Acrodose PL Systemenables blood centres to pool

individual whole-blood derivedplatelets – prior to storage – andconduct a single bacterialcontamination test with itsintegrated Pall eBDS technology.Studies using the eBDS systemwith pooled platelets resulted ingreater than 99 percent detectionof bacteria that can contaminateplatelets, reports Pall.

With the new Acrodose PLsystem, blood centres will be ableto provide hospitals andtransfusion services withAcrodoseSM platelets, atransfusion-ready therapeutic doseof platelets that is bothleukoreduced and bacteria-testedwith a highly-sensitive culture-based method. In turn, hospitalscan reduce their handling costsby eliminating the need forfurther processing and testing,according to Pall.

www.pall.com